Jylamvo

Methotrexate, the active ingredient in Jylamvo, is an antimetabolite presented as an oral tablet for oral use. It modulates immune activity and inhibits cell proliferation, making it useful in treating autoimmune conditions such as rheumatoid arthritis and psoriasis, as well as in the management of selected cancers.

GNH USA supplies Jylamvo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets.

Methotrexate is used in several disease categories where it modulates immune response or inhibits rapidly dividing cells.

Rheumatoid arthritis: reduces joint inflammation and slows structural damage in adult patients. Psoriasis: decreases skin cell proliferation, improving plaque severity. Acute lymphoblastic leukemia: interferes with DNA synthesis to limit malignant cell growth. Osteosarcoma: part of combination chemotherapy to inhibit tumor growth. Ectopic pregnancy: induces resorption of trophoblastic tissue when surgery is not preferred.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or general weakness. - Mouth sores (stomatitis). - Mild decreases in blood cell counts.

Serious or Rare Side Effects: - Hepatotoxicity, potentially leading to liver fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Severe bone marrow suppression causing pancytopenia.

Before initiating therapy, several safety considerations should be addressed. - Renal function: assess baseline kidney function and monitor during therapy. - Liver health: perform liver function tests before initiation and periodically. - Hematologic monitoring: obtain complete blood count regularly to detect cytopenias. - Pregnancy: avoid use in women who are pregnant or may become pregnant unless absolutely necessary. - Concomitant drugs: review use of NSAIDs and other folate antagonists. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Methotrexate interacts with several medicines that can alter its safety or efficacy.

Major Interactions (Avoid): - Live vaccines: may cause severe infection; avoid administration. - High‑dose aspirin: increases risk of toxicity. - Other folate antagonists (e.g., trimethoprim): additive toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce renal clearance. - Proton pump inhibitors: may increase methotrexate plasma levels. - Sulfonamides: potential for enhanced myelosuppression.